MacroGenics to Participate in Upcoming Investor Conference
19 mai 2021 07h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results
29 avr. 2021 16h01 HE
|
MacroGenics, Inc.
MARGENZA™ launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCOConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., April 29, 2021 ...
MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
19 avr. 2021 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
10 avr. 2021 08h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
26 févr. 2021 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
25 févr. 2021 16h01 HE
|
MacroGenics, Inc.
MARGENZA™ approved in December 2020; commercial launch expected March 2021July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumabMultiple clinical updates across...
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
18 févr. 2021 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Names Federica O’Brien to its Board of Directors
11 févr. 2021 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
11 févr. 2021 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
08 févr. 2021 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 08, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...